Printer Friendly

Ono Pharmaceutical Announces Changes in Investigational AIDS Drug Development Program.

Tokyo, Japan, Sept 26, 2005 - (JCNN) - Ono Pharmaceutical has decided to change its development program for ONO-41028/873140, an investigational drug for AIDS treatment. Specifically, the company's development partner GlaxoSmithKline (GSK) has observed elevated liver function test values (AST, ALT and total bilirubin) in the recent Phase IIb studies conducted in North America and Europe.

As a result, GSK has decided to terminate Phase IIB studies in HIV-positive patients who have never taken any AIDS drug. Further, GSK has made some changes to the protocol for phase III clinical studies in HIV-positive patients who have been treated with AIDS drugs.

ONO-4128/873140 is a CCR5 receptor antagonist. Ono Pharmaceutical and GSK entered into a licensing agreement for the agent in December 2002.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Sep 27, 2005
Words:138
Previous Article:Dai Nippon Printing (DNP) Invests in US Molecular Imprint Venture Concern.
Next Article:Matsushita Electric Works Develops Flexible Optoelectronic PCB; Protype at CEATEC Japan 2005.


Related Articles
Faster approval for some drugs.
An overview of the drug approval process. (FDA Overview).
AVEXA IN-LICENSES PHASE II HIV DRUG FROM SHIRE.
Ono Pharmaceutical Announces Termination of Patient Enrollment for Phase III Clinical Trial of Investigational AIDS Drug.
Ono Pharmaceutical, Array BioPharma to Collaborate in Kinase-targeted Drug Discovery.
TIBOTEC UNVEILS U.S. EXPANDED ACCESS PROGRAM FOR TMC114.
Ono Pharmaceutical, Dainippon Sumitomo Pharma to Enter into Joint Development and Marketing Agreement for Limaprost Alfadex, Oral PGE1 Derivative.
Ono Pharmaceutical, Medarex to Collaborate in Research on Fully Human Antibody.
Banyu and Ono Begins Phase III Clinical Trials of a DPP-4 Inhibitor for Type 2 Diabetes Patients.
Ono Pharmaceutical Announces Establishment of Strategic Alliance Headquarters.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters